111, Inc. Reports Third Quarter Financial Results
111, Inc. (NASDAQ: YI), a top-tier tech-enabled healthcare platform dedicated to transforming the healthcare ecosystem through digital empowerment, has announced its unaudited financial results for its third quarter ending September 30, 2025.
Key Developments in Q3 2025
This reporting period featured significant achievements in 111, Inc.’s strategic operations. The company successfully transitioned from a traditional asset-heavy model to a more efficient asset-light approach. This vital change not only enhances profitability but also boosts liquidity by expediting processes and optimizing service delivery.
Financial Highlights
Highlights from the third quarter include:
- Total operating expenses recorded at RMB180.3 million (approximately US$25.3 million), a decrease of 13.4% from RMB208.2 million during the same period last year.
- Quarterly non-GAAP net income stood at RMB1.1 million (about US$0.2 million), consistent with prior quarters in its revenue share.
- Operating cash flow led to positive cash generation, totaling RMB38.1 million (approximately US$5.4 million) this quarter alone.
Strategic Shift Towards Asset-Light Model
Mr. Junling Liu, Co-Founder and CEO, expressed satisfaction with the company’s resilience amid external challenges. He stated, "Our non-GAAP operational profitability for a third consecutive quarter showcases our financial strength. The strategic shift includes divesting three self-operated subsidiaries to focus on partnership opportunities that support our asset-light strategy without sacrificing service quality."
Optimization of Supply Chain
111, Inc. is actively enhancing its supply chain through initiatives such as "MANTIANXING," leading to a nationwide increase in fulfillment centers. These centers boosting inventory values to RMB498 million resulted in 20.5% growth in Gross Merchandise Value (GMV), along with a 31.0% rise in our customer base in comparison to previous quarters.
Future Vision and AI Integration
Looking forward, 111, Inc. aims to establish an AI-driven transaction platform for pharmaceutical procurement. The continuous leverage of AI integration is expected to facilitate smarter decision-making for pharmacies and broaden supplier reach. The overarching goal is to improve the customer journey and potentially reposition the company for sustained value creation.
Financial Results Summary
Net revenues for this quarter amounted to RMB3.0 billion (around US$421.5 million), marking a decline of 16.7% compared to RMB3.6 billion last year. Despite this decrease, the company maintains its focus on profitability measures bolstering its financial health.
Cost Management
- Cost of goods sold reached RMB2.8 billion (US$396.5 million), down by 16.7%, aligning cost management with revenue performance.
- General expenses were RMB15.7 million (approximately US$2.2 million), an upward revision of 9.2% compared to last year's figures.
- Overall financial health signifies that total assets held by the company stood at RMB557.5 million (US$78.3 million), reflecting stable growth.
Strategic Partnerships to Enhance Growth
With a firm commitment to fostering partnerships, 111, Inc. is actively inviting new collaborations to refine its asset-light strategy. The divestiture of select self-operated assets is expected to significantly enhance profitability and service reliability while upholding the quality of work across its networks.
Frequently Asked Questions
What is the main focus of 111, Inc.?
111, Inc. aims to reshape the healthcare value chain by providing digital solutions that empower both upstream and downstream healthcare processes.
How has the company's financial performance changed recently?
This quarter, 111, Inc. reported a decrease in net revenues but achieved operational profitability, showcasing resilience amidst market challenges.
What is the significance of the asset-light model for the company?
The asset-light model reduces financial burdens associated with owning physical assets, allowing for greater flexibility and improved cash flow.
What initiatives are driving growth at 111, Inc.?
Ongoing projects such as the "MANTIANXING" initiative are significantly improving supply chain efficiency and broadening customer outreach.
What is the future vision of 111, Inc.?
111, Inc. aims to develop an AI-powered platform to optimize pharmaceutical procurement, enhancing decision-making capabilities for pharmacies and suppliers.
